OMV Group Schwechat Refinery, © OMV Group

Chemieanlagenbau Chemnitz (CAC) is realizing one of the first large-scale plants in Europe to use innovative co-processing to produce carbon-neutral fuels.

© Ulrike Leone/pixabay.com

Kurma Parnters and France‘e investment bank have launched a €50m project named Argobio that is aimed at identifiying the most genious biotech ideas and spin out companies.

© Rudy and Peter Skitterians /Pixabay.com

British Oxular Ltd has raised $37m in a financing round led by Forbion Parners and co-financed by IP Group, NeoMed, and V-Bio Ventures to push its pipeline.

© Pixabay.com

The European Commission is set to fund ten "European Partnerships" partnered with different industries with €10bn.

Culture of muscle cells in the lab. © MosaMeat

Cultured meat producer MosaMeat BV has announced the third and final closing of its Series B round raising US$85m.

© NIAID

Austrian researchers have found that a lack of activation of the NK receptor is highly associated with severe COVID-19 disease courses.

© Minaris

Swiss cancer vaccine specialist MaxiVAX SA has hired Minaris Regenerative Medicine GmbH to produce its cell therapy MVX-ONCO-2.

©  pearson0612/Pixabay.com

Pfizer Inc. and BioNTech SE have signed an agreement with the European Commission (EC) to supply an additional 200 million doses of BNT162b2 to the EU.

Treated liver tumor under the microscope. While the tumor cells (upper part) are strongly affected by the lipotoxic therapy (formation of characteristic lipid droplets and cell death), normal liver cells (lower part) are only barely affected by the therapy. © Daniel Dauch, University Hospital Tübingen

A resesarch team headed by HepaRegeneriX Board Member Lars Zender has presented a new approach to treat hepatocellular carcinoma (HCC) by disturbing the lipid metabolism of tumour cells. 

Colorized scanning electron micrograph of a natural killer cell from a human donor. © NIAID

Cell therapy specialist Cytovia Therapeutics Inc and genome editing expert Cellectis SAS partner to develop iPSC-derived natural killer (NK) cell-based cancer therapies.